Innoviva Inc (HVE.BE)
| Previous close | 10.20 |
| Open | 10.20 |
| Bid | 10.30 x 0 |
| Ask | 10.40 x 0 |
| Day's range | 10.20 - 10.20 |
| 52-week range | 9.95 - 17.90 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 25 Apr 2023 - 01 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
BURLINGAME, Calif., March 13, 2023--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced that the U.S. Food and Drug Administration’s (FDA) Antimicrobial Drugs Advisory Committee will convene April 17, 2023 to review data supporting the new drug application (NDA) for sulbactam-durlobactam (SUL-DUR).
- Business Wire
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
BURLINGAME, Calif., February 28, 2023--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today reported financial results for the fourth quarter ended December 31, 2022.
- Simply Wall St.
Shareholders in Innoviva (NASDAQ:INVA) are in the red if they invested a year ago
Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...
